Video

know more about us

NASH and quality of life

NASH is part of a multi-system disorder

From number-one liver disease to multi-system disease: NASH, a major unmet clinical need

Imaging biomarkers in NAFLD: Could they avoid liver biopsy

Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany

New insights into liver macrophages in NASH pathogenesis

Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2

Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 1

Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D

Phase 3 development in the field of non-alcoholic steatohepatitis (NASH)

Management of Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: Weight gain with PPAR-γ Agonists

Management of patients with T2D and NAFLD: the role of PPAR-γ

Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

Management of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)

PPAR gamma agonist

Biomarkers in NASH

PPAR’s as critical regulators of metabolism

PPAR alpha delta : what you need to know about the latest results

PPAR alpha gamma dual agonists : what you need to know

NAFLD and states of insulin resistance

The prevalence, risks and costs of NASH

Lipids effects of PPARs by Prof. F. Sacks

Microvesicles as NAFLD biomarkers: a clinician’s point of view by Prof. P. E. Rautou

The link between lipids and PPARs in NASH by Prof. F. Sacks

Liver biopsy in NASH by Prof. P. Bedossa

The multiple risks in NAFLD by Prof. F. Tacke

Liver biopsy in NASH clinical trials by Prof. P. Bedossa

Role of PPARs (experimental paper) by Prof. F. Tacke

NAFLD: time to update the terminology? By Prof. S. Francque

NAFLD: a hegemonic disease by Prof. S. Francque

PPARs: State-of-the-art by Prof. J.-F. Dufour

The role of a global holistic approach in NASH management: important messages

The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician

The role of comorbidities in NASH management: a holistic approach

The role of liver sinusoidal endothelial cells

Pre-clinical study with Lanifibranor – Prof Gracia-Sancho

The role of PPARs in NASH fibrogenesis

What can we expect from PPAR agonists in the treatment of NASH?

The role of PPARs in NASH fibrogenesis

The role of PPARs in inflammation

Important trials during the Liver meeting in Boston

Prof Pierre-Emmanuel Rautou, Paris, France highlights two important abstracts

Prof G. Szabo reviews the learnings about alcohol consumption and liver disease that were presented during the Liver meeting 2019 in Boston.

Prof Jean-François Dufour highlights why the Liver meeting 2019 in Boston is relevant for NASH investigators with presentations of new modes of action and non-invasive biomarkers.

Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting.

Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston. She sees a lot of hope in new clinical trials and new biomarkers.

Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston

Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.

Prof Dufour discusses best practices about the diagnosis of NASH

Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH

Why are PPAR agonists a promising option for the management of NASH ?

Lipotoxicity in NASH

Prof Szabo, USA discusses the progresses of the quest of biomarkers in NASH

Learn more about the burden of the disease, Prof Sven Francque, Belgium

What are the current definitions ? Prof Abdelmalek, USA

An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA

Is NASH only about the liver ?